Acrivon Therapeutics, Inc. (ACRV)
| Market Cap | 61.21M +69.7% |
| Revenue (ttm) | n/a |
| Net Income | -77.27M |
| EPS | -2.00 |
| Shares Out | 42.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 546,250 |
| Open | 1.540 |
| Previous Close | 1.550 |
| Day's Range | 1.405 - 1.540 |
| 52-Week Range | 1.150 - 3.560 |
| Beta | 1.91 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+704.2%) |
| Earnings Date | May 13, 2026 |
About ACRV
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is AC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ACRV stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 704.20% from the latest price.
News
Acrivon Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
ACR-368 demonstrates high response rates in serous endometrial cancer, far surpassing standard care, with rapid trial enrollment and a pivotal interim analysis planned for Q4. The pipeline includes promising assets for lung cancer and AML, supported by a predictive AI-driven platform.
Acrivon Therapeutics Proxy statement: Proxy filing
Acrivon Therapeutics filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing pr...
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing pr...
Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)
“2026 is an important catalyst year for Acrivon as we advance our two differentiated, AP3-guided clinical oncology programs towards key data read-outs,” said Peter Blume-Jensen, chief executive office...
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms i...
Acrivon Therapeutics Earnings release: Q1 2026
Acrivon Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Acrivon Therapeutics Quarterly report: Q1 2026
Acrivon Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Acrivon Therapeutics Slides: Corporate presentation
Acrivon Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Acrivon Therapeutics Proxy statement: Proxy filing
Acrivon Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Acrivon Therapeutics Proxy statement: Proxy filing
Acrivon Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition
Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)
“It’s an exciting time for the company as we build on strong maturing data and clinical momentum,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
Acrivon Therapeutics sees cash runway into 2Q27
As of December 31, 2025, the company had cash, cash equivalents and investments of $118.6 million, which is expected to fund operating expenses and capital expenditure requirements into the second…
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC)
Acrivon Therapeutics Earnings release: Q4 2025
Acrivon Therapeutics released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Acrivon Therapeutics Annual report: Q4 2025
Acrivon Therapeutics has published its Q4 2025 annual report on March 19, 2026.
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (A...
Acrivon Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
A proteomics-driven platform is advancing targeted cancer therapies, with lead asset ACR-368 showing high response rates and favorable safety in serous endometrial cancer. Rapid global trial expansion and a robust pipeline, including a dual WEE1/PKMYT1 inhibitor and a CDK11 inhibitor, support strong clinical and commercial potential.
Acrivon Therapeutics Slides: TD Cowen 46th Annual Health Care Conference
Acrivon Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
Acrivon Therapeutics Transcript: European Society of Gynecological Oncology (ESGO) Congress 2026
ACR-368 showed a 52% response rate and favorable safety in serous endometrial cancer, addressing a major unmet need where current therapies are limited. Experts anticipate broad adoption in second- and third-line settings, with rapid global trial expansion and ongoing FDA engagement for potential accelerated approval.
Acrivon Therapeutics Slides: FY 2026
Acrivon Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on February 27, 2026.
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing p...
Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 ...
Acrivon Therapeutics announces completion, certification of CLIA certified lab
Acrivon Therapeutics (ACRV) announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment, CLIA, certified laboratory, located on prem...